Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
FDA Approves Foundation Medicine Test as CDx for Merck's Keytruda to Identify MSI-H Solid Tumors
The FoundationOne CDx test can now be used as a companion diagnostic for the drug to identify patients with solid tumors that have high microsatellite instability.
FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
HalioDx, FFCD Collaborate for Phase II Metastatic Colorectal Cancer Trial
HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.
Biodesix, Addario Lung Cancer Institute Studying PIR Test Ability to Predict Immunotherapy Response
The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.